NCT05045664View on ClinicalTrials.gov

Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
Interventions
RADIATION

Standard

12 x 2 Gy involved site radiotherapy plus Rituximab

RADIATION

Experimental

2 x2 Gy involved site radiotherapy plus Obinutuzumab

DRUG

Standard

Rituximab with 12 x 2 Gy involved site radiotherapy

DRUG

Experimental

Obinutuzumab with 2 x2 Gy involved site radiotherapy

Trial Locations (12)

10967

RECRUITING

Vivantes Klinikum Berlin, Berlin

18057

RECRUITING

University of Rostock, Rostock

37075

RECRUITING

University of Göttingen, Göttingen

41063

RECRUITING

Strahlentherapie KH Maria Hilf, Mönchengladbach

45147

RECRUITING

University of Essen, Essen

69120

RECRUITING

University Hospital Heidelberg, Heidelberg

72076

RECRUITING

University of Tübingen, Tübingen

81377

RECRUITING

LMU München, Munich

81675

RECRUITING

Technische Universität München, Munich

89081

RECRUITING

University of Ulm, Ulm

93049

RECRUITING

Krankenhaus Barmherzige Brüder, Regensburg

Unknown

RECRUITING

Katharinen Hospital Stuttgart, Stuttgart

All Listed Sponsors
lead

Heidelberg University

OTHER